Clinical trials: Angiofollicular Lymph Hyperplasia
Multicentric Castleman Disease
TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial
To explore the effectiveness and safety of thalidomide, cyclophosphamide and prednisone (TCP regimen) in newly diagnosed Multicentric Castleman's disease (MCD) patients.
- Trial name
- NCT03043105
- Testing
- Thalidomide, cyclophosphamide and prednisone
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking Union Medical College Hospital
Multicentric Castleman's Disease
A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease
The purpose of this study is to evaluate the long-term safety of siltuximab in patients with multicentric Castleman's disease (MCD).
- Trial name
- NCT01400503
- Testing
- Siltuximab
- Where
- 26 sites in United States, Belgium and 15 more
- Volunteers
- 60 people
- Sponsor
- Janssen Research & Development, LLC
Castleman Disease
Nintedanib Treatment in Unicentric Castleman Disease
Unicentric Castleman Disease (UCD) is a rare non-malignant localised disease involving one or more lymph nodes, associating germinal centre atrophy, mantle zone thickening and intense vascular proliferation penetrating the…
- Trial name
- NUCastle (NCT06643091)
- Testing
- Nintedanib
- Volunteers
- 13 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced Solid Tumors, Breast Cancer
Dose-escalation Study of Oral CX-4945
This Phase 1 study of oral CX-4945 is designed to test the safety, tolerability and highest safe dose level of this CK2 inhibitor in patients with advanced solid tumor cancers, Castleman's Disease or Multiple Myeloma.
- Conditions
- Advanced Solid Tumors, Breast Cancer, Inflammatory Breast Cancer, Castleman's Disease
- Trial name
- NCT00891280
- Testing
- CX-4945 oral formulation
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Cylene Pharmaceuticals
Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease, Primary Effusion Lymphoma
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
Background: The chemotherapy combination DA-EPOCH-RP includes the drugs etoposide (E), prednisone (P), vincristine (O), cyclophosphamide (C), doxorubicin (H), rituximab (R), and pomalidomide (P).
- Trial name
- NCT02228512
- Testing
- Pomalidomide, Rituximab, Prednisone
- Sponsor
- National Cancer Institute (NCI)
Castleman Disease, Unicentric Castleman Disease
Unicentric Form of Castleman Disease - Surgery Therapy Benefit
Observation study on patients with unicentric form of Castleman disease, evaluation of surgical treatment benefit. Observation of surgical treatment strategy.
- Conditions
- Castleman Disease, Unicentric Castleman Disease, Surgery
- Trial name
- NCT05440305
- Testing
- surgery type/exstirpation/debulking
- Volunteers
- 20 people
- Sponsor
- Charles University, Czech Republic
Lymphoma, Primary Effusion
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Background: Primary effusion lymphoma (PEL), plasmablastic lymphoma (PBL), and Multicentric Castleman Disease (MCD) are aggressive forms of cancer that affects cells in the immune system and lymph nodes.
- Trial name
- NCT05907759
- Testing
- Daratumumab SC
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Idiopathic Multicentric Castleman's Disease
BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)
To explore the effectiveness and safety of bortezomib, cyclophosphamide and dexamethasone (BCD regimen) in newly diagnosed idiopathic Multicentric Castleman's disease (iMCD) patients.
- Trial name
- NCT03982771
- Testing
- Bortezomib, Cyclophosphamide, Dexamethason
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
HIV Infections, Giant Lymph Node Hyperplasia
Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy
This trial is aimed to study the efficacy of 4 weekly cycles of rituximab in HIV-infected patients with multicentric Castleman disease (giant lymph node hyperplasia) dependent on chemotherapy.
- Trial name
- NCT00127569
- Testing
- Rituximab
- Volunteers
- 25 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Idiopathic Multicentric Castleman's Disease
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
Phase 2 study to investigate the safety, tolerability, and efficacy of administering increased siltuximab doses to patients with iMCD
- Trial name
- SISREMCAD (NCT04838860)
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- RECORDATI GROUP
Castleman's Disease (CD), Langerhans Cell Histiocytosis (LCH)
Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease
The purpose of this study is to use agnostic genomic evaluation using whole exome sequencing (WES) of a variety of rare hematologic diseases grouped under rare blood diseases and its variants to further elucidate the…
- Conditions
- Castleman's Disease (CD), Langerhans Cell Histiocytosis (LCH), Non-Langerhans-Cell Histiocytosis
- Trial name
- NCT05028621
- Testing
- Genetic testing
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Case Comprehensive Cancer Center
Epithelioid Hemangioma of Bone, Epithelioid Hemangioma
Epithelioid Hemangioma of Bone And Soft Tissue
The controversy surrounding epithelioid hemangioma diagnosis stems from its somewhat aggressive clinical characteristics, including multifocal presentation and occasional lymph node involvement.
- Trial name
- EE-META (NCT03169595)
- Testing
- Surgery
- Volunteers
- 70 people
- Sponsor
- Istituto Ortopedico Rizzoli
Chronic Myeloproliferative Disorders, Leukemia
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
RATIONALE: Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Nonneoplastic Condition
- Trial name
- NCT00132015
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
HIV, Kaposi's Sarcoma
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
BACKGROUND: A number of important scientific advances can be made through the study of blood, bone marrow, tumor, or other tissue samples from patients with HIV infection, infection with Kaposi s sarcoma associated herpesvirus…
- Conditions
- HIV, Kaposi's Sarcoma, Lymphomas, Multicentric Castleman's Disease
- Trial name
- NCT00006518
- Where
- United States
- Volunteers
- 1,029 people
- Sponsor
- National Cancer Institute (NCI)
Human Immunodeficiency Virus, Castleman's Disease
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
Background: A person s genome is the collection of all their genes. A gene instructs individual cells to make proteins. Proteins are involved in all of our body s chemical processes.
- Conditions
- Human Immunodeficiency Virus, Castleman's Disease, Kaposi's Sarcoma, Viral-Associated Cancer
- Trial name
- NCT03300830
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Amyloidosis
Registry for Adults With Plasma Cell Disorders (PCD's)
The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric…
- Conditions
- Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease
- Trial name
- NCT03717844
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Kaposi Sarcoma
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
Background: Kaposi sarcoma (KS) is a cancer most often seen in people with HIV. It causes lesions. These are usually on the skin but sometimes in the lymph nodes, lungs, and gastrointestinal tract.
- Trial name
- NCT02659930
- Testing
- liposomal doxorubicin, pomalidomide
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
KSHV Inflammatory Cytokine Syndrome (KICS), Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
Background: Kaposi sarcoma herpesvirus (KSHV)-associated inflammatory cytokine syndrome (KICS) and KSHV-multicentric Castleman disease (MCD) occur in people living with HIV.
- Trial name
- NCT06052618
- Testing
- Pacritinib
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
This phase I trial studies how well rituximab hyaluronidase and combination chemotherapy work in treating patients in Uganda with Burkitt lymphoma, diffuse large B-cell lymphoma, or Kaposi sarcoma herpesvirus associated…
- Conditions
- Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03864419
- Testing
- Rituximab and Hyaluronidase Human, Cyclophosphamide, Vincristine
- Where
- Uganda
- Volunteers
- 18 people
- Sponsor
- Fred Hutchinson Cancer Center
Anti IL-6R, Castleman's Disease, Multicentric
Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease
This study adopted a multicenter, randomized, double-blind, placebo-controlled approach with the best supportive treatment design, using recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) to…
- Trial name
- NCT07872423
- Testing
- Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection
- Where
- 8 sites in China
- Volunteers
- 45 people
- Sponsor
- Beijing VDJBio Co., LTD.